Cerebral palsy has long been more prevalent in males than females, a disparity that points toward X-linked genetic architecture — yet the specific genes driving that bias have remained elusive. New genomic evidence now places the X-linked gene SHROOM4 squarely in the frame, offering a potential molecular explanation for both the sex imbalance and some of CP's clinical heterogeneity.
A whole-exome sequencing study of 1,010 Chinese male CP patients and 1,014 matched male controls identified a specific T-A-G haplotype across three SHROOM4 single-nucleotide variants — rs2873098, rs2295544, and rs2295543 — that carried an odds ratio of 6.09 for CP susceptibility (Pc = 3.26×10⁻⁷). This haplotype was disproportionately represented in CP cases complicated by intrauterine growth restriction. A rare nonsense variant, p.Arg684*, was also found in a patient with spastic CP and intellectual disability. Functional validation using qPCR, immunofluorescence, western blotting, and CRISPR/Cas9 knockout lines showed that both p.Arg684* and a frameshift variant (p.Glu1140fs*42) reduce SHROOM4 transcript levels via nonsense-mediated decay, while residual transcripts generate truncated proteins with variant-specific structural consequences.
SHROOM4 encodes an actin-binding scaffolding protein involved in neural tube morphogenesis and cytoskeletal organization — functions critical during early neurodevelopment. Its prior association with Stocco dos Santos X-linked mental retardation syndrome and other neurodevelopmental conditions makes the CP link biologically plausible rather than incidental. The study's strengths include a reasonably sized cohort by CP genomics standards and multi-modal functional validation. Key limitations include ethnic specificity — the haplotype's frequency and effect size in non-Chinese populations are unknown — and the cross-sectional, case-control design, which cannot establish causality. CP is also etiologically heterogeneous; SHROOM4 variants likely account for a small fraction of total CP burden. Overall, this is a credible incremental advance that adds a tractable X-linked candidate to CP genetic research and may refine future diagnostic sequencing panels for unexplained male CP.